Stock ALTER THERADIAG
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Theradiag

Equities

ALTER

FR0004197747

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Theradiag

Biosynex: merger with Theradiag completed CF
Theradiag SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Theradiag: improved first-half profitability CF
Theradiag: 7% growth in half-year sales CF
Theradiag SA Reports Audited Revenue Results for the Second Quarter and First Half Ended on June 30, 2023 CI
Theradiag SA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Theradiag SA Announces Executive Changes CI
Theradiag SA Announces Management Changes CI
Biosynex SA completed the acquisition of additional 46.52% stake in Theradiag SA for €21.6 million. CI
Theradiag SA Announces Revenue Results for the Year Ended December 31, 2022 CI
Biosynex SA completed the acquisition of 40% stakes in Theradiag SA. CI
French Diagnostics Company Biosynex Offers to Take Over Theradiag MT
Biosynex SA bid to acquire remaining 74.93% stakes in Theradiag SA. CI
Theradiag SA Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Theradiag SA Announces Revenue Results for the Six Months Ended June 30, 2022 CI
Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics CI
Theradiag Announces the Launch of ez-Track, A Point-Of-Care Testing Solution for Therapeutic Drug Monitoring CI
THERADIAG Announces the Launch of Two New i-Tracker® Kits CI
Theradiag Announces Executive Changes CI
Theradiag SA Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Theradiag Signs PCR Test Distribution Agreement With Biosynex MT
Theradiag Announces Signing of A Distribution Agreement with Biosynex of Their AMPLIQUICK SARS-CoV-2 PCR Test CI
THERADIAG Announces the Launch of 4 New i-Tracker? Kits and the Validation of a New Parameter in the United States CI
France's Biosynex Raises Theradiag Stake to Nearly 19% MT
Theradiag Raises $5 Million Via Rights Issue To Fund Expansion MT

Chart Theradiag

Chart Theradiag
More charts

Company Profile

Theradiag develops, produces, and sells in vitro diagnostic kits for detecting auto-immune diseases, allergies, and infectious diseases. The group also offers theranostic tests for monitoring biotherapies and determining patient response to treatments applied. 54.6% of net sales are abroad.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. ALTER Stock
  4. News Theradiag
  5. France's Biosynex Raises Theradiag Stake to Nearly 19%